Adjuvant treatment with ipilimumab, when given at a 3-mg/kg dose, was found to improve overall survival compared with high-dose interferon alfa in patients with high-risk melanoma.
The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.
Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.
Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual International Congress on Immunotherapies in Cancer®. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.
Richard L. Shapiro, MD, discusses the evolution and current role of surgery in advanced melanoma.
Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.
Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.
Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.
Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.
David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.